Novo Nordisk A/S Sees Unusually High Options Volume (NYSE:NVO)

Novo Nordisk A/S (NYSE:NVO) was the target of some unusual options trading on Friday. Traders purchased 100,752 call options on the company. This represents an increase of approximately 58% compared to the average daily volume of 63,882 call options.

Institutional Trading of Novo Nordisk A/S

A number of hedge funds have recently made changes to their positions in the stock. Arrowstreet Capital Limited Partnership acquired a new stake in Novo Nordisk A/S in the first quarter valued at $287,660,000. Boston Partners acquired a new position in Novo Nordisk A/S during the 3rd quarter worth $310,199,000. Price T Rowe Associates Inc. MD grew its holdings in Novo Nordisk A/S by 99.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock worth $492,940,000 after acquiring an additional 4,836,285 shares in the last quarter. Voloridge Investment Management LLC increased its position in shares of Novo Nordisk A/S by 851.6% in the 4th quarter. Voloridge Investment Management LLC now owns 4,807,279 shares of the company’s stock worth $244,594,000 after purchasing an additional 4,302,126 shares during the last quarter. Finally, Maverick Capital Ltd. acquired a new stake in shares of Novo Nordisk A/S in the 1st quarter valued at about $76,444,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Oral Wegovy adoption is emerging as a potential catalyst. Jim Cramer highlighted accelerating pill prescriptions and argued that Wall Street’s initial negative reaction to Novo’s quarterly performance may have overlooked the company’s underlying strength. Jim Cramer Reevaluates Novo Nordisk as Wegovy Pill Adoption Accelerates
• Positive Sentiment: Unusually high call-option activity suggests some traders are positioning for a rebound: investors purchased roughly 100,752 calls, about 58% above typical volume. This is a market signal rather than a change in fundamentals.
• Positive Sentiment: Novo’s CEO Mike Doustdar said the obesity-drug market will not be dominated by a single company, arguing that patients will value differentiated treatments and that oral options could broaden demand. Novo CEO Says Obesity Market Won’t Be Winner-Take-All Battle With Lilly
• Neutral Sentiment: Zacks Research upgraded Novo Nordisk from “strong sell” to “hold,” indicating reduced bearishness but not a bullish recommendation. Erste Group also issued a fiscal-2026 earnings estimate, though no estimate details were provided.
• Negative Sentiment: Eli Lilly is gaining obesity-drug market share, creating concern that Lilly’s injectable and oral therapies could widen its competitive advantage even as Novo reports record prescriptions for oral Wegovy. Can Novo Nordisk’s GLP-1 Pill Momentum Offset Lilly’s Growing Edge?
• Negative Sentiment: The company’s chief executive acknowledged Lilly’s market-share gains, while an escalating marketing dispute highlights intensifying competition in the strategically important weight-loss market. Novo Nordisk Escalates Weight-Loss War With Eli Lilly

Novo Nordisk A/S Stock Down 1.7%

Shares of Novo Nordisk A/S stock opened at $45.91 on Friday. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $64.16. The company has a market capitalization of $204.99 billion, a PE ratio of 11.23, a P/E/G ratio of 4.23 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The business has a 50-day moving average of $47.36 and a 200-day moving average of $44.51.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. The business had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%. As a group, equities analysts forecast that Novo Nordisk A/S will post 3.41 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a dividend, which will be paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th will be given a $0.5786 dividend. This represents a dividend yield of 254.0%. The ex-dividend date of this dividend is Monday, August 17th. Novo Nordisk A/S’s dividend payout ratio is presently 19.80%.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. HSBC reiterated a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, July 6th. Wall Street Zen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Citigroup reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. Weiss Ratings raised shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. Finally, Berenberg Bank set a $47.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday. Four equities research analysts have rated the stock with a Buy rating and sixteen have assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $64.94.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.